EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Endothelial Progenitor-Cell-Derived Exosomes Induced by Astragaloside IV Accelerate Type I Diabetic-wound Healing via the PI3K/AKT/mTOR Pathway in Rats

Wu Xiong, Xue Bai, Xi Zhang, Huajuan Lei, Hui Xiao, Luyao Zhang, Yuting Xiao, Qianpei Yang, Xiaoling Zou

Frontiers in Bioscience-Landmark · 08.11.2023 · 28 (11)

DOI: 10.31083/j.fbl2811282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 08.11.2023. Verfasst von Wu Xiong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Burns and Plastic Surgery, the First Affiliated Hospital of Hunan University of Chinese Medicine, 410007 Changsha, Hunan, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 1, Endothelial Progenitor Cells, Exosomes. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Clinical Medical Technology Innovation Guidance Project of Hunan Provincial Science and Technology Department, Hunan Natural Science Foundation Youth Fund Project, National Natural Science Foundation of China Youth Science Fund Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We explore the effects of endothelial progenitor cell (EPC)-derived exosomes (EPCexos) and of astragaloside IV (ASIV)-stimulated EPCexos (ASIV-EPCexos) on type I diabetic-wound healing, and determine the basic molecular mechanisms of action.

Methods

EPCs were exposed to different concentrations of ASIV to generate ASIV-EPCexos. A chronic-wound healing model involving streptozotocin-stimulated diabetic rats was established. These rats were treated with EPCexos, ASIV-EPCexos, rapamycin, and wortmannin. Wound healing was evaluated by direct photographic observation, hematoxylin and eosin staining, and Masson’s trichrome staining.

Results

ASIV treatment increased the abilities of EPCs (e.g., proliferation), as well as exosome secretion. EPCexo showed a “cup holder” like structure. Treatment with ASIV-EPCexos increased the wound-healing rate, collagen-deposition area, bromodeoxyuridine uptake, VEGF expression, and the number of CD31- and αSMA- positive cells, whereas decreased epidermal thickness and CD45 expression. The expression of the PI3K/AKT/mTOR pathway increased, whereas the expression of inflammatory factor decreased. However, rapamycin and wortmannin reversed these changes.

Conclusions

ASIV-EPCexos may accelerate type I diabetic-wound healing via the PI3K/AKT/mTOR pathway. This study may lay the foundation for new clinical treatment options for patients with type I diabetic wounds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, ExperimentalDiabetes Mellitus, Type 1Endothelial Progenitor CellsExosomesAnimalsRatsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRats, Sprague-DawleySirolimusTOR Serine-Threonine KinasesWortmanninWound HealingSaponinsTriterpenes

Stichwörter der Autor:innen

PI3K/AKT/mTORangiogenesisastragaloside IVendothelial progenitor cellsexosome

Substanzen

Phosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSirolimusTOR Serine-Threonine KinasesWortmanninastragaloside ASaponinsTriterpenesmTOR protein, rat

Autor:innen und Institutionen

  • Department of Burns and Plastic Surgery, the First Affiliated Hospital of Hunan University of Chinese Medicine, 410007 Changsha, Hunan, China.
  • Department of Endocrinology, the First Affiliated Hospital of Hunan University of Chinese Medicine, 410007 Changsha, Hunan, China.
  • Department of Scientific Research, Hunan Brain Hospital, 410007 Changsha, Hunan, China.
  • Clinical Medical School of Hunan University of Chinese Medicine, 410007 Changsha, Hunan, China.
  • Department of Anesthesiology, the First Affiliated Hospital of Hunan University of Chinese Medicine, 410007 Changsha, Hunan, China.
  • College of Integrated Traditional Chinese and Western Medicine, Hunan University of Chinese Medicine, 410208 Changsha, Hunan, China.

Förderung

  • Clinical Medical Technology Innovation Guidance Project of Hunan Provincial Science and Technology Department
  • Hunan Natural Science Foundation Youth Fund Project
  • National Natural Science Foundation of China Youth Science Fund Project
  • Science and Health Joint Project of Hunan Natural Science Foundation

Zitieren

APA

Xiong, W., Bai, X., Zhang, X., Lei, H., Xiao, H., Zhang, L., Xiao, Y., Yang, Q., & Zou, X. (2023). Endothelial Progenitor-Cell-Derived Exosomes Induced by Astragaloside IV Accelerate Type I Diabetic-wound Healing via the PI3K/AKT/mTOR Pathway in Rats. Frontiers in Bioscience-Landmark, 28(11). https://doi.org/10.31083/j.fbl2811282

Vancouver

Xiong W, Bai X, Zhang X, Lei H, Xiao H, Zhang L, et al. Endothelial Progenitor-Cell-Derived Exosomes Induced by Astragaloside IV Accelerate Type I Diabetic-wound Healing via the PI3K/AKT/mTOR Pathway in Rats. Frontiers in Bioscience-Landmark. 2023;28(11). doi:10.31083/j.fbl2811282

BibTeX
@article{Xiong2023,
  author = {Xiong, Wu and Bai, Xue and Zhang, Xi and Lei, Huajuan and Xiao, Hui and Zhang, Luyao and Xiao, Yuting and Yang, Qianpei and Zou, Xiaoling},
  title = {Endothelial Progenitor-Cell-Derived Exosomes Induced by Astragaloside IV Accelerate Type I Diabetic-wound Healing via the PI3K/AKT/mTOR Pathway in Rats},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2023},
  volume = {28},
  number = {11},
  doi = {10.31083/j.fbl2811282}
}
Kostenlos starten →